PTSD – Medxy AI

Psychedelics and MDMA for Mental Disorders: Promising Large Effects but Limited Certainty—What the Latest Living Meta-analysis Shows

By MedXY 11/25/2025

A living systematic review of 30 RCTs (n=1,480) finds moderate-to-large symptom reductions for MDMA in PTSD and serotonergic psychedelics in major depression and anxiety, but high risk of bias and low certainty overall; pragmatic, longer, and blinded trials are needed.

Family Medicine & Nutrition news Psychiatry

Comparative Effectiveness of PTSD Treatments in Primary Care: Insights from a Pragmatic Randomized Trial

By MedXY 10/15/2025

A pragmatic trial comparing SSRIs and written exposure therapy in primary care PTSD treatment found similar effectiveness initially; switching to SNRI was superior to WET augmentation for SSRI nonresponders.

Emergency Medicine news Psychiatry

Which Mental-Health Steps Should Trauma Teams Prioritize? A Practical Synthesis of New Guideline Recommendations

By MedXY 10/10/2025

A systematic synthesis of clinical practice guideline recommendations for preventing and managing mental disorders after traumatic injury, with prioritized, implementable actions for acute and early recovery care.